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Abstract
The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that interrupt proliferation of malignant 
cells by inhibiting progression through the cell cycle. Three such inhibitors, palbociclib, ribociclib, and abemaciclib were 
recently approved for breast cancer treatment in various settings and combination regimens. On the basis of their impressive 
efficacy, all three CDK4/6 inhibitors now play an important role in the treatment of patients with HR+, HER2− breast cancer; 
however, their optimal use still needs to be established. The three drugs have many similarities in both pharmacokinetics and 
pharmacodynamics. However, there are some differences on the basis of which the choice for a particular CDK4/6 inhibitor 
for an individual patient can be important. In this article, the clinical pharmacokinetic and pharmacodynamic profiles of 
the three CDK4/6 inhibitors are reviewed and important future directions of the clinical applicability of CDK4/6 inhibitors 
will be discussed.
Key Points 
CDK4/6 inhibitors play an eminent role in the treatment 
of advanced HR+, HER2− breast cancer and are of 
potential value in the (neo)adjuvant setting.
Biomarkers need to be identified to optimize the therapy 
in patients treated with CDK4/6 inhibitors and to select 
patients with other types of (breast) cancer who could 
potentially benefit.
Combinations with other drug modalities with a different 
pharmacodynamic profile need to be defined to further 
enhance the efficacy, overcome resistance, and widen the 
applicability of CDK4/6 inhibitors.
1 Introduction
Of all patients with stage IV breast cancer, approximately 
75% are hormone receptor-positive (HR+) and human epi-
dermal growth factor receptor 2 negative (HER2−) [1–3]. As 
advanced or metastatic breast cancer represents an incurable 
disease, the main purpose of treatment is to delay disease 
progression, preferably with anticancer drugs that are patient 
friendly in their use and toxicity [4]. Patients with HR+, 
HER2− breast cancer are often treated with single-agent 
endocrine therapy. However, endocrine resistance always 
develops, resulting in the need for cytotoxic chemotherapy 
[5–7].
Recently, a novel drug class, the cyclin dependent kinase 
(CDK) 4/6 inhibitors, has been introduced as a treatment 
option for patients with HR+, HER2− advanced breast can-
cer, either as first-line therapy combined with an aromatase 
inhibitor or as second-line therapy in combination with ful-
vestrant [8–13]. The CDK-RB1-E2F pathway targeted by 
CDK4/6 inhibitors is essential for progression through the 
cell cycle and is disrupted in the majority of cancers [14–18]. 
In breast cancer, the activation of estrogen receptors as well 
as other proliferation-inducing signals stimulate the compl-
exation of CDK4/6 with cyclin D1 [19]. Binding of CDK4/6 
to cyclin D1 induces phosphorylation of the retinoblastoma 
(Rb) tumor suppressor protein, releasing its inhibitory effect 
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and thereby providing the starting signal for cell division 
[16, 18, 20–22]. Normally, CDK4 and CDK6 are inhibited 
by the protein p16. However, in cancer this mechanism of 
cell cycle control is often disrupted [19, 23]. Furthermore, 
cyclin D1, the binding partner of CDK4/6, is often over-
expressed in patients with HR+, HER2− breast cancer 
leading to continuous activation of the cyclin D1–CDK4/6 
complex [24–26]. Inhibition of CDK4/6 induces complete 
dephosphorylation of Rb, resulting in sequestration of the 
transcription factor E2F and subsequent inhibition of cell 
cycle progression [27–29].
The effectiveness of CDK4/6 inhibitors can be increased 
by combining them with drugs that prevent the downstream 
estrogen-dependent stimulation of the cancer cell. Inhibition 
of the estrogen pathway—by endocrine therapy—results in 
downregulation of cyclin D1 and reduced complexation of 
CDK4 and CDK6 [30]. Therefore, the selective CDK4/6 
inhibitors palbociclib, ribociclib, and abemaciclib are given 
in combination with endocrine therapy (aromatase inhibi-
tors or fulvestrant) in the treatment of HR+, HER2− breast 
cancer [31–33].
So far, no head-to-head comparison has been carried 
out between the three different CDK4/6 inhibitors in HR+, 
HER2− advanced breast cancer. At present, CDK4/6 inhibi-
tors are prescribed based on individual physicians’ expe-
rience with these CDK4/6 inhibitors, differences in toxic-
ity profiles, costs, or the preference policy of the hospital. 
Insights into pharmacological profiles of these three CDK4/6 
inhibitors may help to rationalize the selection of the most 
optimal inhibitor for the individual patient. In this review, 
the pharmacokinetics, pharmacodynamics, efficacy, and tol-
erability of palbociclib, ribociclib, and abemaciclib for the 
treatment of breast cancer are discussed. Furthermore, future 
directions of the clinical applicability of the CDK4/6 inhibi-
tors are discussed such as the potential role of biomarkers in 
determining treatment strategy in specific patient groups, the 
combination with other drug modalities, and the use of these 
therapies in other types of (breast) cancer (Fig. 1).
2  Pharmacokinetics
2.1  Pharmacokinetic Profiles
Palbociclib  (Ibrance®, Pfizer, New York, USA) received 
US FDA approval in 2015, with a recommended starting 
dosage of 125 mg once daily in a ‘3 weeks on and 1 week 
off’ schedule in combination with a non-steroidal aromatase 
inhibitor or the selective estrogen receptor degrader (SERD) 
fulvestrant [32]. After rapid absorption of palbociclib, the 
maximum concentration (Cmax) is achieved within 6–12 h 
and the drug is being eliminated with an elimination half-life 
of 24–34 h. Steady-state will be achieved after 4–5 elimina-
tion half-lives, which is important to predict the onset of 
action or improvement of toxicity after treatment discontinu-
ation. Ribociclib  (Kisqali®, Novartis, Basel, Switzerland) 
Fig. 1  Mechanism of action of CDK4/6 inhibitors. The CDK4/6-cyc-
lin D1 complex induces phosphorylation of the retinoblastoma (Rb) 
tumor-suppressor protein. Free transcription factor E2F stimulates 
cell transition from the G1 to the S phase and cell division. AKT pro-
tein kinase B, CDK4/6 cyclin dependent kinase 4 and 6, ER estrogen 
receptor, E2F transcription factor family, HER2 human epidermal 
growth factor receptor-2, PIK3 phosphoinositide 3-kinase, Rb retino-
blastoma tumor suppressor protein, mTOR mammalian target of rapa-
mycin
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received US FDA approval in 2017, with a recommended 
starting dosage of 600 mg once daily in a ‘3 weeks on/1 
week off’ schedule in combination with an aromatase inhibi-
tor or fulvestrant [33]. Ribociclib has a high absorption rate 
and reaches Cmax within 1–4 h upon intake. The elimina-
tion half-life of ribociclib is 30–55 h. Finally, abemaciclib 
 (Verzenios®, Eli Lilly, Indianapolis, USA) received US FDA 
approval in 2017, with a recommended starting dosage of 
150 mg twice daily in a continuous dosing schedule com-
bined with an aromatase inhibitor or fulvestrant. In addition, 
abemaciclib is also approved for administration as mono-
therapy with a starting dosage of 200 mg twice daily [31]. 
Abemaciclib achieves its Cmax within 8 h upon intake and 
the drug elimination half-life is 17–38 h. Pharmacokinetic 
parameters of palbociclib, ribociclib, and abemaciclib are 
depicted in Table 1.
2.2  Similarities and Differences 
in Pharmacokinetics
2.2.1  Absorption
The pharmacokinetic profiles of the three inhibitors are 
strikingly similar. After rapid absorption and distribution, 
all three CDK4/6 inhibitors are metabolized mainly by 
CYP3A4. Abemaciclib is given in a continuous schedule 
of two doses per day, whereas palbociclib and ribociclib are 
given once daily in ‘3 weeks on/1 week off’ schedules. Only 
for abemaciclib, preclinical studies have displayed saturation 
of drug absorption, which supported the development and 
registration of a twice-daily dosing regimen to improve drug 
absorption [34, 35]. Furthermore, preclinical studies showed 
that continuous administration of abemaciclib reduced 
Table 1  Pharmacokinetics of palbociclib, ribociclib, and abemaciclib
bid twice daily, cLog P calculated Log P (lipophilicity), Cmax, maximum concentration, Ctrough trough concentration, CV coefficient of variation, 
M metabolite, NR not reported, qd once daily, T½ half-life, Tmax time to reach maximum observed concentration
Palbociclib  (Ibrance®)
PD-0332991 [10, 32, 42, 50, 105–108]
Ribociclib  (Kisqali®)
LEE011 [33, 50, 71, 115]
Abemaciclib  (Verzenios®)
LY2835219 [31, 34, 39, 77, 116–118]
First US FDA approval
In combination with an 
aromatase inhibitor or 
fulvestrant
2015 2017 2017
Molecular weight (g/mol) 447.54 434.55 506.59
cLog P 2.7 2.3 5.5
Route of administration Oral Oral Oral
Dose 125 mg qd; 3 weeks on/1 week off 600 mg qd; 3 weeks on/ 1 week off 150 mg bid; continuously
Dosage form and strengths Capsules Tablets Tablets
75, 100, 125 mg 200 mg 50, 100, 150, 200 mg
Ctrough (ng/mL) 47 (CV; 48%) 457 (CV; 67%) 176 (CV; 89%)
Tmax (h) 6–12 1–4 8
Cmax (ng/mL) 97 (CV; 41%) 1680 (CV; 31%) 249 (CV; 64%)
T½ (h) 24–34 30–55 17–38
Bioavailability (%) 46 NR 45
Accumulation ratio 2.4 (1.5–4.2) 2.51 (0.97–6.40) 3.2 (CV; 59%)




Distribution (L) 2583 1090 690.3
Metabolism CYP3A4 + SULT2A1 CYP3A4 CYP3A4
Metabolites Yes Yes Yes
M13 (N-hydroxylation): 22% M2 (N-desethylation): 25%
Palbociclib-glucuronide: 1.5% M4 (N-demethylation): 20% M20 (hydroxylation): 26%
M1 (secondary glucuronide): 18% M18 (hydroxy-N-desethylation): 13%
Excretion (%) Feces: 74 Feces: 69 Feces: 81
Urine: 18 Urine: 23 Urine: 3
Age, weight, gender, 
race, mild hepatic/renal 
impairment
No effect on exposure No effect on exposure No effect on exposure
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tumor growth more efficiently compared with an intermit-
tent schedule [34–36]. The efficacy of palbociclib and ribo-
ciclib in continuous dosing schedules compared with the 
efficacy of the current intermittent schedule is unknown, 
but hematological toxicities urged the development of an 
intermittent schedule.
2.2.2  Distribution
From a biopharmaceutical point of view, a distinguishing 
feature of abemaciclib in comparison with the other CDK4/6 
inhibitors is its theoretical ability to penetrate breast tissue 
and the blood–brain barrier more efficiently due to its higher 
lipophilicity (cLog P 5.5 versus 2.7 and 2.3, see Table 1). In 
support of this theoretical advantage, preclinical data from 
abemaciclib in human xenograft models showed decreased 
tumor growth in the brain, and when compared with palbo-
ciclib and ribociclib, abemaciclib had the highest unbound 
brain-to-plasma ratio, suggesting effective penetration [38]. 
In addition, a clinical study indicated that systemic treat-
ment with abemaciclib resulted in similar concentrations of 
abemaciclib in both plasma and cerebrospinal fluid [39]. In 
addition, both palbociclib and ribociclib are substrates for 
breast cancer resistance protein (BCRP; ABCG2) and P-gly-
coprotein (P-gP; ABCB1), which is an additional explana-
tion for their limited brain penetration capacity observed in 
preclinical studies [40, 41]. The efficacy of the three dif-
ferent CDK4/6 inhibitors in treating brain metastases is an 
important unanswered question in daily clinical practice. 
Prospective trials are ongoing to evaluate brain penetra-
tion and efficacy of palbociclib (NCT02774681), ribociclib 
(NCT02933736), and abemaciclib (NCT02308020) in the 
treatment of brain metastases.
2.2.3  Metabolism and Excretion
For all three CDK4/6 inhibitors, metabolization occurs 
hepatically, and was shown by both in vitro and in vivo 
studies to be primarily mediated by CYP3A4. Concomitant 
administration of CDK4/6 inhibitors and strong CYP3A4 
inhibitors (i.e., itraconazole, ketoconazole, and ritonavir) can 
lead to an increase in exposure of CDK4/6 inhibitors in the 
blood and an increased chance of toxicity. The administra-
tion of palbociclib in combination with the strong CYP3A4 
inhibitor itraconazole resulted in an increase in area under 
the concentration–time curve from zero to infinity (AUC 
0–inf) and Cmax of 87% and 34%, respectively; ribociclib in 
combination with ritonavir increased ribociclib exposure up 
to 3.2-fold; and based on an animal model, ketoconazole is 
predicted to increase the exposure of abemaciclib by up to 
16-fold. The FDA therefore advises to avoid concomitant 
use of CDK4/6 inhibitors and strong CYP3A4 inhibitors 
[31–33].
Yu et al. published a physiologically based pharmacokinetic 
model—based on silico, in vitro, and in vivo pharmacokinetic 
data—in which they simulated the effects of the moderate 
CYP3A4 inhibitors verapamil and diltiazem on palbociclib 
pharmacokinetics. They estimated an increase in Cmax and 
AUC of 22% and 38% for verapamil and 23% and 42% for 
diltiazem, respectively. The authors concluded that the risk of 
drug–drug interactions for palbociclib co-administered with 
moderate CYP3A4 inhibitors is relatively modest and that 
no upfront dose adjustment is needed [42]. However, a 40% 
increase in exposure could still be clinically relevant, espe-
cially since a higher palbociclib exposure is associated with 
increased toxicity [42]. A clear relationship between exposure 
and toxicity is not described in literature for either ribociclib or 
abemaciclib. More research is needed to elucidate the plausible 
relationship between exposure and adverse events. Currently, 
a randomized pharmacokinetic cross-over trial is ongoing to 
evaluate the effect of the moderate CYP3A4 inhibitor eryth-
romycin on the pharmacokinetics of palbociclib (Netherlands 
Trial Register NL7549) and results are expected in 2021.
2.2.4  Metabolism and Pharmacogenetics
Besides CYP3A4-mediated metabolism, palbociclib is also 
hepatically metabolized by the sulfotransferase enzyme 
SULT2A1 [43]. SULTs, such as SULT2A1, are highly 
expressed in the small intestine, liver, and adrenal cortex and 
metabolize orally administered drugs through sulfate con-
jugation. Pharmacogenetic variation in SULT2A1 activity 
could affect the drug’s biotransformation and thus its phar-
macokinetics [44]. Variability in CYP3A4 and SULT2A1 
drug metabolization can often be partly explained by genetic 
polymorphisms. The extent to which this applies for all three 
CDK4/6 inhibitors is unclear and requires further research. 
Sequencing of CYP3A4 and SULT2A1 genes in patients 
treated with CDK4/6 inhibitors may potentially identify 
subpopulations requiring dose adjustments. The incidence 
of any neutropenia and grade 3 neutropenia specifically is 
higher in the Asian population compared with non-Asian 
patients treated with palbociclib [10, 45], concordant with 
the observed higher mean steady-state concentration of pal-
bociclib [45]. The reason for differences in pharmacokinet-
ics between Asian and non-Asian populations is unknown, 
but could be related to genetic predispositions influencing 
metabolism or higher numbers of CDK receptors and/or sen-
sitivity of the receptors [46].
3  Pharmacodynamics
CDK4 is a prominent oncogenic driver in breast cancer, 
while CDK6 plays a crucial role in differentiation of 
hematopoietic stem cells [47, 48]. Palbociclib, ribociclib, 
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and abemaciclib display subtle differences in kinase selec-
tivity. Abemaciclib is the most potent CDK4/6 inhibitor 
and is approximately five times more potent against CDK4 
than CDK6, which leads to the expectation that abemaci-
clib exerts less hematological toxicity (Table 2) [34, 37, 
49]. Preclinical drug-exposure experiments showed inhi-
bition of CDK4 and CDK6 with half maximal inhibi-
tory concentrations  (IC50) of 9–11 nM and 15 nM (ratio 
 IC50 CDK4:CDK6 is 1:1.5) for palbociclib, 10 nM and 
39 nM (1:4) for ribociclib, and 2 nM and 9.9 nM (1:5), 
for abemaciclib, respectively [50, 51]. In contrast to pal-
bociclib and ribociclib, abemaciclib was shown to be a 
potent inhibitor of CDK9 as well [50]. CDK9 inhibition 
could potentially modify the cascade of glycogen synthase 
kinase 3 (GSK3)-mediated effects of abemaciclib leading 
to the specific intestinal toxicity observed [52, 53].
Table 2  (Pre)clinical pharmacodynamics and efficacy of palbociclib, ribociclib, and abemaciclib
HR hazard ratio, mo months, NR not reported, IDFS invasive disease free survival
Palbociclib  (Ibrance®)
PD-0332991 [8, 11, 50, 55, 63, 
119]
Ribociclib  (Kisqali®)
LEE011 [9, 13, 50, 119, 120]
Abemaciclib  (Verzenios®)
LY2835219 [10, 50, 58, 62, 119]
CDK4, IC50 9–11 nM 10 nM 2 nM
CDK6, IC50 15 nM 39 nM 9.9 nM
CDK9, IC50 NR NR 57 nM
Advanced setting
Efficacy first line
Median PFS vs aromatase inhibi-
tor alone (mo)
24.8 vs 14.5 (HR 0.58; p < 0.001) 25.3 vs 16.0 (HR 0.56; p < 0.001) Not reached vs 14.7 (HR 0.54; 
p < 0.001)
Median OS (mo) NR NR NR
Efficacy second line
Median PFS vs fulvestrant alone 
(mo)
9.5 vs 4.6 (HR 0.46; p < 0.001) 20.5 vs 12.8 (HR 0.59; p < 0.001) 16.4 vs 9.3 (HR 0.55; p < 0.001)
Median OS (mo) 34.9 vs 28.0 (HR 0.81; p = 0.09) Not reached vs 40.0 (HR 0.72; 
p = 0.005)
46.7 vs 37.3 (HR 0.76; p = 0.014)
Toxicity advanced setting  (all/
grade 3–4) (%)
Neutropenia (80/66) Neutropenia (75/60) Neutropenia (41/22)
Anemia (24/5) Anemia (18/1) Anemia (28/6)
Thrombocytopenia (16/1) Thrombocytopenia (29/1) Thrombocytopenia (10/2)
Diarrhea (26/1) Diarrhea (35/1) Diarrhea (81/9)
Fatigue (37/2) Fatigue (37/2) Fatigue (46/3)
ALT increased (43/2) ALT increased (46/10) ALT increased (48/6)
Creatinine increased (NR/NR) Creatinine increased (20/1) Creatinine increased(98/2)
Infections (60/7) Infections (50/4) Infections (39/5)
Dosing patterns advanced setting Dose reduction: 36% Dose reduction: 54% Dose reduction: 43%
Dose interruptions: 67% Dose interruptions: 76% Dose interruptions: 56%
Permanent discontinuation: 7.4% Permanent discontinuation: 7.5% Permanent discontinuation: 20%
Adjuvant setting
Efficacy adjuvant setting
Proportion with IDFS event (%)
5.9% in the palbociclib arm vs 
6.3% in control arm (HR 0.93; 
p > 0.05)
NR 4.8% in the abemaciclib arm vs 




Neutropenia (83/61) NR Neutropenia (45/19)
Anemia (23/1) Anemia (23/2)
Thrombocytopenia (21/1) Thrombocytopenia (12/1)
Diarrhea (17/1) Diarrhea (82/8)
Fatigue (41/2) Fatigue (38/3)
Upper respiratory infections (28/1) Upper respiratory infections (10/0)
Dosing patterns adjuvant setting Dose reduction: NR NR Dose reduction: 41%
Discontinued prematurely: 42% Discontinuation prematurely: 17%
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4  Clinical Efficacy
4.1  Advanced Breast Cancer
The effects of the CDK4/6 inhibitors palbociclib, riboci-
clib, and abemaciclib in combination with non-steroidal 
aromatase inhibitors were studied in postmenopausal ER+, 
HER2− advanced breast cancer in the first-line setting in 
three large randomized phase III trials, PALOMA-2 (pal-
bociclib), MONALEESA-2  (ribociclib), and MON-
ARCH-3 (abemaciclib) [8–10]. All three CDK4/6 inhibi-
tors significantly prolonged the progression free survival 
(PFS) with almost identical hazard ratios (HR) for PFS 
(Table 2). Overall survival (OS) data for these studies are 
not available yet. However, an OS benefit was found in the 
MONALEESA-7 trial, which investigated the addition of 
ribociclib to the gonadotropin-releasing hormone (GnRH) 
agonist goserelin with either tamoxifen or a non-steroidal 
aromatase inhibitor in pre- or perimenopausal women (HR 
0.71; 95% CI 0.54–0.95) [54].
The effects of CDK4/6 inhibitors in addition to ful-
vestrant mainly during the second line of treatment in 
patients with HR+, HER2− advanced breast cancer were 
studied in the three large randomized phase III trials; 
PALOMA-3 (palbociclib), MONALEESA-3 (ribociclib), 
and MONARCH-2 (abemaciclib) [12, 13, 55]. All phase 
III trials showed prolongation of the PFS in the CDK4/6 
inhibitor group as well as an OS benefit [56–58].
Based on the above described results, CDK4/6 inhibi-
tors are registered for first- and second-line treatment in 
advanced HR+, HER2− breast cancer patients. Their most 
optimal position during treatment (i.e., first or second line) 
is a matter of debate (59–61), and is being investigated in 
the currently ongoing randomized phase III SONIA trial 
(ClinicalTrials.gov identifier NCT03425838) [61]. Due 
to the unique study design, this study will also allow for 
a head-to-head comparison of the three FDA-approved 
CDK4/6 inhibitors to identify the differences in clinical 
pharmacology.
4.2  Adjuvant Setting
The positive results in the advanced breast cancer set-
ting raised interest in CDK4/6 inhibitors as potential 
treatments in the neo-adjuvant and adjuvant setting. For 
all three CDK4/6 inhibitors, large randomized phase III 
trials are currently ongoing to investigate the addition 
of a CDK4/6 inhibitor to standard adjuvant endocrine 
therapy (NCT03701334) [62, 63]. In the MonarchE trial, 
the addition of abemaciclib treatment for 2 years in post-
menopausal, high risk HR+, HER2− early breast cancer 
(EBC) patients is explored [62]. After a median follow-up 
of 15.5 months, 136 of the 2808 patients (4.8%) experi-
enced recurrence of invasive disease in the abemaciclib 
arm compared with 187 of the 2829 patients (6.6%) in the 
control arm (HR 0.75; 95% CI 0.60–0.93) [62]. Almost 
all patients experienced adverse events in the abemaciclib 
arm (97.9%), with grade ≥ 3 adverse events reported in 
45.9% of patients compared with 86.1% and 12.9% in the 
endocrine monotherapy group, respectively. In total, 463 
patients (16.6%) discontinued abemaciclib due to these 
treatment-related adverse events. These results are in con-
trast with those of the PALLAS trial, which was termi-
nated early following the interim analysis since no effect 
of additional palbociclib to adjuvant endocrine therapy 
was found. After a median follow-up of 23.7 months, 170 
of the 2883 patients (5.9%) in the palbociclib arm experi-
enced recurrence of invasive disease compared with 181 of 
the 2877 patients (6.3%) in the control arm (HR 0.93; 95% 
CI 0.75–1.14). A remarkably high premature discontinu-
ation rate of 42% was observed in the palbociclib arm of 
this study, which was attributed to adverse events in 64% 
of these patients.
These contradictory results in effectiveness raise ques-
tions. One important difference between these two trials is 
the study population. Whereas the PALLAS study included 
all patients with stage 2–3 EBC, the MonarchE study spe-
cifically included patients with high-risk EBC, defined as 
patients with four or more positive pathologic lymph nodes 
or patients with one to three pathologic lymph nodes com-
bined with either tumor size ≥ 5 cm, histologic grade 3, 
or centrally assessed Ki-67 proliferation index of ≥ 20%. 
Subgroup analyses of only patients with N2–N3 disease and 
patients with clinically high risk (≥ 4 nodes or 1–3 nodes 
with either T3–T4 and/or grade 3 disease) disease in the 
PALLAS trial still did not show a significant effect in recur-
rence rate with addition of palbociclib, suggesting differ-
ences in study population may not be the main cause for 
the difference in study outcome. However, cross-study com-
parison should be interpreted with caution. Furthermore, 
follow-up imaging for the presence of recurrence was not a 
protocol requirement, but was performed at the discretion 
of the treating medical oncologist. In combination with the 
open-label design of the MonarchE trial, this could intro-
duce confounding by indication bias by a likely tendency 
to more often perform a scan in high-risk EBC patients in 
the placebo arm compared with the CDK4/6 inhibitor arm. 
This could lead to more frequently detected recurrences in 
patients in the placebo arm compared with patients in the 
abemaciclib arm.
Longer follow-up data of trials are needed to confirm 
the clinical benefit of CDK4/6 inhibitors in the adjuvant 
setting, including the impact on OS. Several other studies 
in the adjuvant setting are still ongoing. The NATALEE 
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trial (NCT03701334) is a study in the adjuvant setting in 
which ribociclib is added to endocrine treatment for 3 years. 
Recruitment is ongoing and no results are presented or pub-
lished yet. The PENELOPE-B trial (NCT01864746) stud-
ies the addition of palbociclib to endocrine therapy for 1 
year in patients with a high risk of recurrence based on the 
CPS-EG score, a risk score based on clinical stage before 
neoadjuvant treatment, pathological stage after neoadjuvant 
treatment, nuclear grade, and estrogen receptor status. The 
results are eagerly awaited as, when comparable effectivity is 
reached with additional palbociclib for 1 year compared with 
2 years in the MonarchE trial, this would be advantageous 
to patients and decrease healthcare costs.
4.3  Neoadjuvant Setting
The addition of CDK4/6 inhibitors in the neoadjuvant set-
ting could potentially increase antiproliferative effects on 
the primary tumor before surgery takes place and ultimately 
result in an improved OS. Although no long-term clinical 
outcomes have been published yet in the neoadjuvant setting, 
several studies have shown an increase in cell cycle arrest 
with the addition of a CDK4/6 inhibitor to neoadjuvant 
endocrine treatment. In the NeoPalAna trial, a complete cell 
cycle arrest, as determined by the Ki67 index, was reached 
in a significantly higher proportion of the patients who 
received palbociclib and anastrazole compared with patients 
who received anastrazole monotherapy [64]. The addition 
of ribociclib to letrozole during six cycles in the neoadju-
vant setting was explored in the FELINE trial. It showed a 
higher number of patients with a complete cell cycle arrest 
after 2 weeks of treatment in the ribociclib group compared 
with the placebo group, although at surgery no difference in 
proportion of patients with complete cell cycle arrest was 
found [65]. The NeoMonarch trial showed a reduction in 
Ki67 when abemaciclib was added to anastrazole compared 
with anastrazole monotherapy after 2 weeks of treatment 
[66]. In all studies, the number patients with a complete cell 
cycle arrest decreased after discontinuation of the CDK4/6 
inhibitor, which indicates the importance of continuation of 
CDK4/6 inhibition until surgery takes place.
5  Tolerability
The main side effects of CDK4/6 inhibitors are bone marrow 
suppression—such as neutropenia, anemia, and thrombope-
nia—and gastrointestinal toxicities. However, there seem to 
be some distinct differences between the three drugs. Inter-
estingly, despite these differences in toxicity profiles, all 
three CDK4/6 inhibitors showed comparable EORTC QLQ-
C30 quality-of-life scores [67–69]. Approximately 40–50% 
of patients treated in phase III trials needed a dose reduction 
in cycle 1 or 2 (Table 2). Importantly, permanent discontinu-
ation was reported more often with abemaciclib treatment 
(20%) compared with palbociclib and ribociclib (both 7.5%) 
[8–10]. The most common reasons for dose modification 
were myelosuppression for palbociclib and ribociclib and 
diarrhea for abemaciclib.
5.1  Neutropenia
Grade 3–4 neutropenia—scored by the common terminology 
criteria for adverse events (CTCAE)—was the most reported 
adverse event for palbociclib (66%) and ribociclib (60%) 
and was the second most reported adverse event in patients 
treated with abemaciclib (22%). Neutropenia is usually 
observed in the first cycles of both palbociclib and riboci-
clib. Median time from first dose to onset of first episode of 
neutropenia grade ≥ 3 is 28.0 (12–854) days with a median 
duration of 7 days [70]. Also, for abemaciclib, neutropenia 
often occurs in the first cycle, however in some cases a more 
delayed onset of neutropenia was observed in cycle 2 or later 
[10, 32, 71, 72]. Febrile neutropenia was observed at low 
frequency in patients treated with a CDK4/6 inhibitor (2% 
for both palbociclib and ribociclib and < 1% for abemaci-
clib) [8, 10, 13]. A pharmacokinetic and pharmacodynamic 
model suggested that higher palbociclib exposure was asso-
ciated with lower absolute neutrophil counts [73]. However, 
in general, no clear correlation between race and toxicity 
was found in all phase III trials [8–11, 13, 58]. Therefore, 
more research is needed to identify pharmacokinetic targets 
for the three CDK4/6 inhibitors.
5.2  Gastrointestinal Toxicity
Grade 3 diarrhea (i.e., an increase of seven or more stools a 
day) was more frequently reported in patients treated with 
abemaciclib (9%) compared with palbociclib and ribociclib 
(both 1%) (Table 2) [8–10, 52, 74, 75]. Median time to onset 
of diarrhea was 6 days with a median duration of 6–8 days. 
The highest rate of diarrhea was noticed in the first cycle and 
decreased in following cycles [76]. Prevention of diarrhea is 
important, since this side effect can negatively impact drug 
absorption. A population pharmacokinetic and pharmaco-
dynamic model demonstrated that administration of abe-
maciclib 200 mg twice daily resulted in proportionally less 
drug absorption than administration of 150 mg twice daily 
[77]. An explanation for this phenomenon is the increasing 
incidence of gastrointestinal toxicity and diarrhea at higher 
abemaciclib doses, resulting in decreased absorption as a 
consequence of disrupted intestinal endothelial cells [39, 
77]. In most patients, this side effect does not lead to drug 
discontinuation. If there are no signs of infections, diarrhea 
can be treated with dietary modifications, hydration, and 
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loperamide or other antidiarrheal agents. After recovery, a 
dose reduction can be considered [31].
5.3  QTc Prolongation
Following ribociclib administration, the QTc interval 
might be prolonged, whereas the other two drugs are not 
associated with a clinically relevant QTc time prolonga-
tion (> 20 ms) at the recommended dosing schedules [31, 
79]. Therefore, QTc prolongation seems to be rather drug 
specific, instead of a class effect of CDK4/6 inhibitors 
[80]. QTc prolongation (on average 22.9 ms) was mainly 
observed in the first cycle of ribociclib in combination 
with endocrine therapy. In the MONALEESA-2 trial, 
11 patients (3.3%) were diagnosed with a QTc prolonga-
tion up to > 480 ms in combination with letrozole. In the 
MONALEESA-7 trial, a higher incidence of QTc prolon-
gation (> 60 ms from baseline) was reported in patients 
receiving ribociclib in combination with tamoxifen (16%) 
compared with the combination of ribociclib and a non-
steroidal aromatase inhibitor (7%) [81]. Based on this, 
concomitant intake of ribociclib and drugs with a known 
potential for QTc prolongation—such as anti-arrhythmic 
drugs—should be avoided or closely monitored [80].
6  Future Perspectives
6.1  Refining CDK4/6 Inhibitor Therapy by Using 
Biomarkers
Despite the fact that many HR+, HER2− advanced 
BC patients respond well to CDK4/6 inhibitors in the 
first line of treatment, in subsequent lines the response 
period is evidently shorter and in the end all patients will 
develop resistance to CDK4/6 inhibitors. Consequently, 
predictive and prognostic biomarkers are needed to fur-
ther refine CDK4/6 inhibitor treatment of advanced HR+/
HER2− BC patients. In the large, randomized, controlled, 
phase III SONIA trial (NCT03425838), the optimal posi-
tion of CDK4/6 inhibitors in HR+, HER2− advanced 
breast cancer in the first- or in second-line treatment set-
ting will be determined. Important secondary aims of this 
phase III trial are to investigate the possible associations 
between pharmacokinetics, pharmacodynamics, and cir-
culating tumor DNA (ctDNA) markers for each CDK4/6 
inhibitor in relationship to clinical outcome [61]. The 
identification of biomarkers will be of importance both 
for selection of responsive patients and the optimization 
of the therapeutic response within a patient.
6.1.1  Biomarkers Reflecting Sensitivity or Resistance 
to CDK4/6 Inhibitors
Biomarkers reflecting increased activity of the CDK-RB1-
E2F pathway in tumor cells could help to identify patients 
who are sensitive to CDK4/6 inhibitor treatment. However, 
within the PALOMA-1 trial, the use of CCND1 amplifica-
tion or p16 loss as additional biomarkers for patient selection 
did not result in an improved PFS compared with all ER+/
HER2− patients [84]. Vice versa, identification of resist-
ance mechanisms may yield biomarkers to identify tumors 
resistant to CDK4/6 inhibitors. Whole exome sequencing 
of CDK4/6 inhibitor-exposed breast cancer tissues identi-
fied eight potential resistance mechanisms, including RB1 
loss, activating alterations in AKT1, RAS, AURKA, CCNE2, 
ERBB2, and FGFR2, and loss of ESR1 expression, together 
explaining 66% of the observed resistance [85]. In the 
PALOMA-3 trial, RB1 mutations were acquired in 5% of 
patients after treatment with palbociclib, RB1 deletions were 
observed more frequently but no evidence was found for 
selection of RB1 deletion during treatment [87, 88]. Next to 
RB1, particularly the E-type cyclins, encoded by the CCNE1 
and CCNE2 genes, appear to represent promising mark-
ers of resistance. High cyclin E expression was observed 
in preclinical models with acquired resistance to CDK4/6 
inhibitors [88] and gene expression analyses of breast can-
cer tissues from the PALOMA-3 study showed that low 
expression of CCNE1 before treatment start was associated 
with a longer PFS [89]. In the NeoPalAna trial described 
above, expression of CCNE1, CCND3, and CDKN2D genes 
remained elevated during treatment with CDK4/6 inhibitors 
only in non-responding patients [64]. Large clinical trials 
have to confirm this potential value of cyclin E proteins for 
identification of CDK4/6-resistant patients.
6.1.2  Biomarkers in Liquid Biopsies
Liquid biopsies, usually referring to detection of tumor-
specific DNA fragments in a patient’s blood, represent a 
promising means for real-time monitoring of treatment 
response. Targeted next-generation sequencing analyses on 
blood-derived cell-free DNA (cfDNA) from baseline sam-
ples were performed in the PALOMA-3 trial and showed 
that copy number gains of FGFR1, CDK4, MYC, CCNE1, 
and MCL1 as well as p53 mutations were associated with a 
decreased PFS in patients treated with fulvestrant and pal-
bociclib. However, in multivariable analysis, FGFR1 gain, 
TP53 mutations, and estimated ctDNA tumor fraction were 
significantly associated with PFS, irrespective of treatment 
arm. Results of this study demonstrate that no specific altera-
tion at baseline was associated with PFS specifically in the 
palbociclib group [85].
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In the same cohort, PIK3CA and ESR1 mutations were 
determined at baseline and after 2 weeks of treatment only 
in the palbociclib arm. Interestingly, a decrease in the level 
of detected mutant PIK3CA molecules, but not ESR1 muta-
tions, within the first 2 weeks of CDK4/6 inhibitor treatment 
was associated with a longer PFS. Although this phenom-
enon is probably not CDK4/6-inhibitor specific and is likely 
to reflect ctDNA tumor fraction (i.e., the amount of tumor-
derived DNA in the blood), it could provide a potential tool 
for early monitoring of treatment response irrespective of 
treatment [86].
6.1.3  Therapeutic Drug Monitoring (TDM)
For many drugs, it has been shown that optimization of drug 
dosage by plasma concentration within a predefined thera-
peutic window—also known as therapeutic drug monitor-
ing (TDM)—improves clinical outcome or reduces toxicity 
[92–94]. For CDK4/6 inhibitors, this represents an interest-
ing concept as well. However, at present a minimal effective 
concentration has not been established for any of these three 
agents. On the other hand, the correlation between palboci-
clib exposure and toxicity suggests that we can improve the 
tolerability by dose reductions [42, 73]. Further research is 
needed to investigate whether the current practice of tox-
icity-guided dose adaptations can be further improved by 
implementing TDM.
6.2  Widening the Application of CDK4/6 Inhibitors
6.2.1  HER2+ Breast Cancer
Several studies have shown that a crosstalk exists between 
HER2 signaling and estrogen receptor pathways in a bidi-
rectional way, which make CDK4/6 inhibitors an attrac-
tive therapeutic option in this breast cancer subtype [95]. 
In a preclinical study it has been shown that the CDK4/6 
pathway could mediate resistance against HER2− targeted 
therapies [96]. A phase II randomized trial explored the 
safety and efficacy of the combination of abemaciclib plus 
fulvestrant with trastuzumab in HR+, HER2+ breast cancer 
patients [97]. Patients were included after at least two lines 
of therapy in the advanced setting. The experimental com-
bination of trastuzumab plus abemaciclib and fulvestrant in 
comparison with trastuzumab plus standard-of-care chemo-
therapy of physician’s choice showed a PFS of 8.3 months 
versus 5.7 months in the standard-of-care arm (HR 0.67; 
95% CI 0.45–1.00). This study confirms preclinical data and 
is promising since a significant increase in PFS is present, 
even after two or more lines of treatment. However, results 
of phase III studies are needed to confirm this effectiveness.
6.2.2  Triple‑Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a heterogeneous 
and aggressive type of breast cancer with limited therapeutic 
options. Currently, CDK4/6 inhibitors do not play a role in 
the treatment since efficacy is expected to be limited. Sev-
eral preclinical and clinical studies are examining a role for 
CDK4/6 inhibitors in TNBC with diverse biological ration-
ales and hypotheses. TNBC can be divided into subgroups 
by gene expression profiling: luminal-AR, mesenchymal, 
basal-like immune-suppressed, and basal-like immune-
activated [98]. Experiments in TNBC cell lines have shown 
that these subtypes differ in their sensitivity to CDK4/6 inhi-
bition, with the luminal-AR subtype being more sensitive to 
CDK4/6 inhibitors, whereas the basal-like subtype is highly 
insensitive. These results indicate that patients with TNBC 
should be selected based on their subgroup for treatment 
with CDK4/6 inhibitors [99].
Research is ongoing into newly developed CDK4/6 inhib-
itors in combination with other drug modalities in breast 
cancer. A phase II trial explored the benefit of an addition 
of trilaciclib, a novel CDK4/6 inhibitor, to chemotherapy 
(gemcitabine and carboplatin) in patients with metastatic 
TNBC. An improvement of antitumor effect and in the toler-
ability of chemotherapy by myelopreservation was observed 
in patients who received additional trilaciclib [100]. One of 
the hypotheses to explain the observed effect is the enhance-
ment of antitumor immunity by trilaciclib [101], an effect 
of CDK4/6 inhibitors that has recently raised more inter-
est. Based on the foregoing information, phase III trials in 
which TNBC patients are selected based on their underlying 
subtype are needed to further explore the potential effects of 
adding CDK4/6 inhibitors to chemotherapy.
6.2.3  CDK4/6 Inhibitors and Chemotherapy
CDK4/6 inhibitors and chemotherapy target different phases 
of the cell cycle. CDK4/6 inhibitors induce cell cycle arrest 
in the G0–G1 phase, preventing cells from entering subse-
quent phases of the cell cycle. This antagonizes the effect of 
classic chemotherapeutics, of which the main mode of action 
takes place in these subsequent phases. Several preclinical 
studies in breast cancer explored the effect of treatment with 
CDK4/6 inhibitors followed by chemotherapy. Monotherapy 
was superior to the combination of these therapies [102, 
103]. Interestingly, a preclinical study in pancreatic can-
cer showed that reversing the order of treatments by giving 
CDK4/6 inhibitors after chemotherapy could increase the 
effect of chemotherapy by repressive effects on homolo-
gous recombination proteins [104]. Based on these studies, 
sequence and timing of therapies seems to be essential to 
reach optimal antitumor effects. Further preclinical inves-
tigations potentially followed by clinical studies in breast 
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cancer are warranted to explore the implications for future 
clinical use of CDK4/6 inhibitors after DNA-damaging 
therapies.
6.2.4  HR+, HER2− Breast Cancer
Next to CDK4/6-RB1 signaling, PI3K/AKT/mTOR signal-
ing is an important growth stimulatory pathway in HR+, 
HER2− metastatic breast cancer. One of the described 
mechanisms of resistance to CDK4/6 inhibition is the PI3K-
dependent activation of the cyclin D1/CDK2 complex. This 
complex could phosphorylate pRb leading to S-phase entry 
independent of CDK4/6. Blocking the activation of cyclin 
D1 by inhibiting PIK3CA could be a strategy to overcome 
this resistance, which was effective in cell line experiments 
[88]. Similarly, mTORC1/2 inhibitors have shown potency 
to restore sensitivity to CDK4/6 inhibitors in resistant ER+ 
breast cancer cell lines [105]. Combining fulvestrant, a 
CDK4/6 inhibitor, and a PIK3CA inhibitor, as was explored 
in breast cancer patients with advanced disease in a phase I 
trial, results in promising efficacy and safety. A retrospec-
tive clinical trial found a limited effect of palbociclib when 
it was given after progression on everolimus, which suggests 
a role for mTOR inhibitors during or after CDK4/6 inhibitor 
treatment [106]. These studies imply that additional treat-
ments that block the PI3K/AKT/mTOR signaling pathway 
could be of value in overcoming resistance and prolonging 
the anti-tumor effects of CDK4/6 inhibitors. Sequence and 
timing will be essential and biomarkers are needed to deter-
mine the optimal sequence and timing of treatment on the 
individual patient level.
6.2.5  Other Tumor Types
Since aberrations in the CDK-RB1-E2F pathway are fre-
quently observed in many types of tumors, it is expected 
that CDK4/6 inhibitors have a wider applicability than in 
breast cancer alone. Amplification of cyclin D (CCND1), for 
example, is described in non-small lung cancer, melanoma, 
and endometrial cancer, among others. Several clinical tri-
als in these tumor types are ongoing and the first encourag-
ing results have been presented [39]. A recently performed 
phase II trial in patients with HR+ recurrent or advanced 
endometrial cancer showed a prolongation in PFS with the 
addition of palbociclib to letrozole [107].
In addition, several preclinical studies suggest other 
potential mechanisms of action of CDK4/6 inhibitors that 
could be of interest for the application in other types of 
tumors as well. For example, the ability of CDK4/6 inhibi-
tors to increase the capacity of tumor cells to express anti-
gens and enhance T cell infiltration was shown in vitro [108]. 
This suggests CDK4/6 in combination with immune check-
point blockades could be of interest in specific tumor types. 
However, possible applications first need to be explored fur-
ther in clinical trials.
6.3  New Types of CDK4/6 Inhibitors
Research is ongoing into the novel CDK4/6 inhibitors 
lerociclib (NCT03455829; NCT02983071) and trilaciclib 
(NCT02978716; NCT03041311; NCT02514447) in com-
bination with other targeted therapies or chemotherapy 
in lung and breast cancer. Preclinical work showed a dif-
ferent pharmacokinetic and pharmacodynamic profile for 
lerociclib compared with the other CDK4/6 inhibitors, 
since lerociclib accumulated in xenograft tumors but not 
in plasma [109]. This resulted in less inhibition of myeloid 
progenitor cells. A recently performed phase I/II trial of 
lerociclib in patients with HR+, HER2− metastatic breast 
cancer showed the potential clinical benefits of lerociclib 
since a low rate of both neutropenia grade 3 or 4 and gas-
trointestinal adverse events was seen compared with the 
other CDK4/6 inhibitors [110]. These results await con-
firmation in phase III trials. Trilaciclib differs from the 
clinically available CDK4/6 inhibitors since it is adminis-
tered intravenously and is developed to be combined with 
chemotherapy, mainly to reduced side effects. As earlier 
described, the first phase I/II trial showed promising 
results in terms of efficacy.
7  Conclusions
CDK4/6 inhibitors—palbociclib, ribociclib, and abemaci-
clib—play an eminent role in the treatment of advanced 
breast cancer. The pharmacokinetics, pharmacodynam-
ics, and efficacy of the three CDK4/6 inhibitors seem to 
be comparable, although there are also interesting differ-
ences such as ability for brain penetration, side effects, 
and dosing schedules. These differences between the 
three CDK4/6 inhibitors can be used to optimize selec-
tion of treatment for individual patients. Further research 
is needed to investigate the optimal treatment sequence 
of CDK4/6 inhibitors in different breast cancer settings 
and different subtypes and to develop (pharmacodynamic) 
biomarkers for selecting patients, predicting response, and 
to optimize the treatment schedule.
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